Related Experiment Video

Updated: Aug 22, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

C-reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis

Robert Y L Zee1, Hillary H Hegener, Arturo Fernandez-Cruz

  • 1Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA. rzee@rics.bwh.harvard.edu

Atherosclerosis
|September 24, 2004
PubMed

Insights

This study investigated genetic variants in the C-reactive protein (CRP) gene and their association with restenosis after coronary angioplasty. No significant link was found between CRP gene polymorphisms and restenosis risk in patients.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Epidemiology
  • Interventional Cardiology

Background:

  • Plasma C-reactive protein (CRP) levels are established predictors of restenosis post-coronary angioplasty.
  • CRP levels exhibit heritability, suggesting a potential genetic influence.
  • Limited genetic-epidemiological data exist on CRP gene variants and restenosis risk.

Purpose of the Study:

  • To investigate the association between specific C-reactive protein (CRP) gene polymorphisms (1059G > C and T > A) and the risk of restenosis after angioplasty.
  • To analyze haplotype frequencies of CRP gene variants in relation to restenosis.

Main Methods:

  • A cohort of 779 post-angioplasty patients, including 342 who developed restenosis, was analyzed.
  • Genotyping for CRP gene polymorphisms (1059G > C, T > A) and haplotype analysis were performed.
  • Logistic and linear regression models, adjusted for confounders, were used to assess associations.

Main Results:

  • Genotype and allele distributions for the studied CRP gene polymorphisms were similar between restenosis cases and controls.
  • Haplotype frequency distributions also showed no significant differences between cases and controls.
  • Statistical analyses, including haplotype-based regression, yielded null results, indicating no association.

Conclusions:

  • The tested polymorphisms and haplotypes within the C-reactive protein (CRP) gene are not associated with restenosis risk following coronary angioplasty.
  • Further research may be needed to explore other genetic factors or environmental influences on post-angioplasty restenosis.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...